TCM Syndrome Differentiation Decoction

ApprovedSmall molecule

GGuangzhou University of Traditional Chinese Medicine

TCM Syndrome Differentiation Decoction is one of 79 small molecule programs targeting Cardiovascular Disease. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cardiovascular DiseaseActive, not recruiting

Diabetes MellitusActive, not recruiting

Cardiovascular DiseaseApproved

Active, not recruiting

Diabetes MellitusApproved

Active, not recruiting

Competition

Competitive Landscape

286 competitors in Diabetes Mellitus

#DrugCompanyPhaseTrials

Brevibloc

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

1 2

Lispro

Eli Lilly

Phase 3

1 3

TCM Syndrome Differentiation Decoction

GGuangzhou University of Traditional Chinese Medicine

Approved

1 4

Trulicity

Eli Lilly

Preclinical

2 5

Byetta

AstraZeneca

Preclinical

2 6

NOVOLIN R

Novo Nordisk

Preclinical

1 7

Galvus

Novartis

Preclinical

1 8

Simponi

Johnson & Johnson

Preclinical

1 9

Paxil CR

GSK

Preclinical

1 10

Edarbi

Takeda

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Post-ApprovalNot yet recruiting

Diabetes Mellitus

NCT07121088

Post-ApprovalNot yet recruiting

Cardiovascular Disease

NCT07088523

Clinical

Trials by Indication[1]

Diabetes Mellitus1 trial

Traditional Chinese Medicine Intervention for Ischemic Cerebrovascular Disease and Diabetes Mellitus: An Efficacy Comparative Study

Not yet recruiting·GGuangzhou University of Traditional Chinese Medicine·Phase 4·NCT07121088·3,666 enrolled

Cardiovascular Disease1 trial

Traditional Chinese Medicine Intervention for Ischemic Cardiovascular Disease Comorbid With Diabetes Mellitus: An Efficacy Comparative Study

Not yet recruiting·GGuangzhou University of Traditional Chinese Medicine·Phase 4·NCT07088523·4,205 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for TCM Syndrome Differentiation Decoction. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TCM Syndrome Differentiation Decoction compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TCM Syndrome Differentiation Decoction. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Guangzhou University of Traditional Chinese Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: GGuangzhou University of Traditional Chinese Medicine

TCM Syndrome Differentiation Decoction

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Diabetes Mellitus1 trial

Cardiovascular Disease1 trial

References

Drug Info

Quick Facts

Related News